From: Stetler-Stevenso, Maryalice (NCI) (stetler@mail.nih.gov)
Date: Fri May 10 2002 - 07:43:21 EST
Being at NIH means I don't know standard practice in the private sector. However, there are so many treatments for CLL I can't believe that all will receive CAMPATH-1H. As CLL is an indolent disease and antigen expression does change in time, I wonder the wisdom of looking at CD52 up front. A patient may go 10 years without treatment. In 10 years time we may not use CAMPATH-1H anymore. We look at CD52 when it is requested. We look at CD20 all the time because it is an important B cell antigen and it's level of expression is of diagnostic use in CLL- not because we expect Rituxamab treatment (although the later is true too). I would be interested to hear what others are doing on a routine basis in CLL- at diagnosis and when treatment is necessary. Maryalice Stetler-Stevenson, M.D., Ph.D. Chief, Flow Cytometry Unit Laboratory of Pathology, NCI, NIH Sometimes you're the windshield, sometimes you're the bug. > ---------- > From: Andrea Illingworth > Sent: Thursday, May 9, 2002 1:53 PM > To: Cytometry Mailing List > Subject: CD52 in patients with CLL > > Dear group, > What is the current consensus regarding flow cytometric analysis of CD52 > in CLL's for CAMPATH-1H treatment? Are flow labs performing CD52 staining > on all of their CLL's and are most clinicians using this information for > treatment decisions? > > Thank you for your help! > > Andrea Illingworth, MS, H(ASCP) > Dahl-Chase Flow Cytometry > 333 State Street > Bangor, Maine 04401 >
This archive was generated by hypermail 2.1.6 : Thu Jan 01 2004 - 17:41:41 EST
